Compugen Ltd. · NASDAQ:CGEN
Compugen — Investor Presentation (September 2015)
37 slides from Compugen's investor presentation, September 2015
Slide 1: Predictive Discovery of First-in-Class Biologics
PREDICTIVE DISCOVERY OF FIRST-IN-CLASS BIOLOGICS Primary focus on immuno-oncology Corporate Overview September, 2015 www.cgen.com 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as “will,” “may,” “expects,” “anticipates,” “believes,” and “intends,”
Slide 3: Company Overview
Company Overview Leadership in Predictive Drug Discovery Broadly applicable discovery infrastructure Mission Discover high value novel targets and develop first-in-class biologics for key medical needs Business Model Selectively partner first-in-class biologics at various stages under revenue
Slide 4: Company Fact Sheet
Company Fact Sheet Strong Intellectual Property Landscape Proprietary algorithms and computational biology platforms 54 issued and allowed patents, 132 pending patent applications, in all major countries Experienced Multidisciplinary Teams ~90 employees, 70% R&D Algorithm development, co
Slide 5: Two Centers of Excellence
Two Centers of Excellence Compugen Ltd. Compugen USA Inc. Tel Aviv, Israel South San Francisco, USA Headquarters Wholly-Owned Subsidiary Predictive Target Discovery Therapeutic mAb & Experimental Validation Research & Development 5
Slide 6: Scientific Advisory Board
Scientific Advisory Board Renowned oncologists and immunologists Drew Pardoll, MD, PhD (Chairman of the SAB) Professor of Oncology and Director of Cancer Immunology Program at Johns Hopkins School of Medicine, the Sidney Kimmel Comprehensive Cancer Center Charles G. Drake, MD, PhD Associate Prof
Slide 7: From the Genome to the Clinic: Predictive Discovery
From the Genome to the Clinic An Integrated Approach PREDICTIVE PIPELINE STRATEGIC PREDICTIVE DISCOVERY PROGRAM PARTNERSHIPS DISCOVERY 7
Slide 8: Observational Path of Pharma to Novel Targets
Observational Path of Pharma to Novel Targets COLLECTION OF DISEASE KNOWN GENES / PROTEINS SAMPLES EXPERIMENTAL CHARACTERIZATION DATA ANALYSIS NOVEL TARGETS FIRST-IN-CLASS Known proteins/genes, Diseases-specific, Assays systems limitation No learning 8
Slide 9: Leaders in Predictive Biology
Leaders in Predictive Biology Merging computational biology and translational medicine 15 YEARS OF SCIENTIFIC INFRASTRUCTURE DEVELOPMENT Broadly applicable, consists of multiple discovery platforms APPLIED TO NOVEL DRUG TARGET DISCOVERY FOR FIRST-IN-CLASS BIOLOGICS 9
Slide 10: Unique Infrastructure for Predictive Discovery - The Basic Concept
Unique Infrastructure for Predictive Discovery - The Basic Concept Integration Computational Target Process Model Candidates Novel findings, Short timelines, Continuous learning 10
Slide 11: Paradigm Shift Applicable To Multiple Fields
Paradigm Shift Applicable To Multiple Fields Keddem Bioscience Ltd. Ag-Bio Diagnostic Small Evogene Ltd. Biomarkers Molecule [NYSE: EVGN; TASE: EVGN] Neviah Genomics Drugs JV with Merck-Serono A Private Company Based on Compugen’s Predictive Discovery Capabilities 11
Slide 12: From the Genome to the Clinic: Pipeline Program
From the Genome to the From the Genome to Clinic the Clinic An Integrated Approach An Integrated Approach PREDICTIVE PIPELINE STRATEGIC PIPELINE DISCOVERY PROGRAM PARTNERSHIPS PROGRAM 12
Slide 13: Our Pipeline Program
Our Pipeline Program Novel Targets for First-in-Class Opportunities Oncology 11 novel 4 novel 5 target candidates for immune checkpoint immunomodulatory antibody drug conjugates target candidates target candidates (ADC) Immunology At present: One program for autoimmune diseases Programs based on Com
Slide 14: The Next Wave in Immuno-Oncology Targets
The Novel NextTargets WaveforinFirst-in-Class Immuno-Oncology Opportunities Novel Targets The Nextfor Wave First-in-Class Opportunities in Immuno-Oncology Eleven Five high priority programs Novel Immune in internal pipeline Checkpoint Targets Two partnered programs ONCOLOGY FOUR TARGET Immunomodulat
Slide 15: From the Genome to the Clinic: Strategic Partnerships
From the Genome to the From the Genome to Clinic the Clinic An Integrated Approach An Integrated Approach PREDICTIVE PIPELINE STRATEGIC STRATEGIC DISCOVERY PROGRAM PARTNERSHIP PARTNERSHIPS 15
Slide 16: Collaborative Alliances to Drive High-Value Programs
Collaborative Novel TargetsAlliances to Drive for First-in-Class Opportunities High-Value Programs The Next Wave in Immuno-Oncology Multiple programs to be advanced through a combination of internal development and collaborations Enter collaborations at both early and later stage of development
Slide 17: Bayer Partnership
Bayer Partnership Novel Targets for First-in-Class Opportunities Strategic TheCollaboration Next WavetoinDevelop Cancer Immunotherapies Immuno-Oncology Early stage collaboration and license agreement for antibody-based cancer therapeutics (Aug 2013) Collaboration includes two novel immune checkpoi
Slide 18: First Focused Discovery Program
First Focused Discovery Program Novel B7/CD28 immune checkpoints for cancer immunotherapy Harnessing the immune system to destroy cancer A breakthrough approach to cancer therapy 18
Slide 19: First Focused Discovery Program: Novel B7/CD28 Immune Checkpoints
First Focused Discovery Program Novel B7/CD28 immune checkpoints for cancer immunotherapy Breakthrough approach to cancer therapy Impressive, long-lasting clinical benefits Checkpoint-based drugs expected to become the largest drug class in history 2020 sales estimate $20bn (BMO November 201
Slide 20: Targeting Immune Checkpoints in Oncology Today
Targeting Immune Checkpoints in Oncology Today Crowded Competition on Same Targets PIII PIII PC PII PI PC Undisclos PC ed D Pathways D M PII M PC M PI PII PC PII PC PI PC PC PC PI PC PC PI PC PC PC PC PC 20 PC
Slide 21: Novel Immune Checkpoint Target Discovery
Applying our Predictive Approach: Novel Immune Checkpoint Target Discovery CGEN-15001t CGEN - 15029 CGEN-15022 Undisclosed CGEN-15049 Undisclosed CGEN-15027 Undisclosed CGEN-15052 Undisclosed CGEN-15092 Partial data sources shown for illustrative purposes B7 refers to B7/CD28 21
Slide 22: First Focused Discovery Program
First Focused Discovery Program Novel B7/CD28 immune checkpoints for cancer immunotherapy Results of several months of Compugen’s focused discovery Harnessing the immune system to destroy cancer A Breakthrough approach to cancer therapy Antibody Locations of removes theare“brakes,” CGEN candidates a
Slide 23: Bayer HealthCare Partnership: Current Status
Bayer HealthCare Partnership: Current Status Next Targets for Anti-Tumor Immunity Early stage collaboration and license agreement for antibody-based cancer therapeutics (Aug 2013) • CGEN-15001T and CGEN-15022: Two membrane proteins, novel immune checkpoints • Targets expressed on numerous types of s
Slide 24: CGEN-15049 Expressed in Solid Tumors, Inhibits NK and T-Cell Activation
CGEN-15049 is Expressed in Solid Tumors and Inhibits NK and T-Cell Activation Human tumors Mouse tumors Cohen and Safion, Bar Ilan Univ. Myeloid cells (CD45+CD14+ CD3-) Anti-PDL-1 Myeloid cells (CD45+CD14+ CD3-) Anti-15049 Cancer cells (CD45-) Anti-15049 T cells (CD45+ CD3+) Anti-15049 25
Slide 25: CGEN-15027 Increased Expression in Breast and Lung Tumors
CGEN-15027 Demonstrates Increased Expression in Breast and Lung Tumors and Inhibits T-cell Activation 26
Slide 26: CGEN-15029: New High Priority mAb Program
CGEN-15029: New High Priority mAb Program High TIL Correlation Inhibition of CTL Activation Renal carcinoma Identified Binding Partner 15029-Fc Fc-control 26
Slide 27: Diversified Portfolio of Immuno-Oncology Targets
Diversified portfolio of immuno-oncology targets Genomic Detection Leading to Diverse Set of Novel Candidates Novel inhibitory pathways Primary expression subpopulation shown for illustrative purposes only CGEN candidate 27
Slide 28: Differentiating Features of Compugen Immune Checkpoint Programs
Differentiating Features of Compugen Immune Checkpoint Programs Expression MOA Target Indications Expression in relevant Novel inhibitory Patients and indications cell types, with unique pathways; opportunity to refractory to existing regulation relative to combine with other checkpoint inhibitors k
Slide 29: Multi-Year Immuno-Oncology Collaboration with Johns Hopkins
Multi-Year Immuno-Oncology Collaboration with Johns Hopkins School of Medicine • Focused on the Company’s novel immune checkpoint target candidates • Led by Johns Hopkins Professor Drew Pardoll and Dr. Charles Drake • Supports and accelerates translation to the clinic • Target characterization and d
Slide 30: Second Focused Discovery Program: Targets for ADC-based Cancer Therapies
Second Focused Discovery Program: Targets for ADC-based cancer therapies Antibody-Drug Conjugate (ADC) therapy: selective delivery limits damage to healthy tissue Target proteins on the surface of cancer cells Compugen developed a proprietary ADC discovery platform To date, predicted five potential
Slide 31: ADC Target Candidates Have Highly Restricted Expression
ADC Target Candidates Have Highly Restricted Expression • Low expression in normal Program B critical tissues Normal vs Cancer Analysis • High expression in multiple cancer types Program A Overexpression in Adenocarcinomas Lung 31
Slide 32: Program A Antibody Drug Conjugate
Program A Antibody Drug Conjugate Potent Killing of a Target Expressing Cancer Cell Line FACS Binding Cytotoxic Activity 1000000 C lo n e 1 - A D C C lo n e 1 a lo n e Ig G 1 - A D C 800000 Ig G 1 a lo n e r e la t iv e lig h t u n its 600000 400000 200000 0 0 .0 1 0 .1 1 10 100 nM Multiple high-aff
Slide 33: Two Key Differentiators for Compugen
Two Key Differentiators for Compugen Focus on Novel Targets Pipeline Program based on predicted novel targets Significant opportunity for first-in-class drugs Broad IP landscape Reliance on Predictive Discovery Predict new linkages to disease mechanism Discover multiple target candidat
Slide 34: From the Genome to the Clinic: Validating Milestones
From the Genome to the Clinic Validating Milestones Future hPOC in clinical trials Partnered or un-partnered programs Product-oriented collaborations Collaborations at various development stages (Bayer 2013) Development milestones in collaborations Milestones achieved in Bayer collaborat
Slide 35: Current Financial Status
Current Financial Status Strong Financial Position Cash balance ~$96 million (June 30 ,2015) No Debt 2015 Expected Cash Flow Cash expenditures 2015 ~$31m-$33m* (FCST) Market Capitalization ~$300 million (August 2015) NASDAQ (CGEN); Index – NBI (Nasdaq Biotech Index) TASE (CGEN.TA);
Slide 36: 2015 and Beyond
2015 and Beyond…. Investing in the infrastructure of tomorrow's medicines PREDICTIVE PIPELINE STRATEGIC DISCOVERY PROGRAM PARTNERSHIPS Further leadership in Multiple immuno- Maximize potential predictive discovery oncology programs profit from competitive • Continue to enhance • Advance in parallel
Slide 37: Predictive Discovery of First-in-Class Biologics
PREDICTIVE DISCOVERY OF FIRST-IN-CLASS BIOLOGICS Primary focus on immuno-oncology Corporate Overview September, 2015 www.cgen.com